Capacity for resolution of Ras-MAPK-initiated early pathogenic myocardial hypertrophy modeled in mice

Comparative Medicine

Volumn 61, Issue 2, 2011, Pages 109-118

  Wei, Bih Rong ^a   Martin, Philip L ^a   Hoover, Shelley B ^a   Spehalski, Elizabeth ^a,b   Kumar, Mia ^a   Hoenerhoff, Mark J ^a,c   Rozenberg, Julian ^a   Vinson, Charles ^a   Simpson, R Mark ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN DEPENDENT KINASE INHIBITOR 1C; CYCLINE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; RAS PROTEIN; ATRIAL NATRIURETIC FACTOR; CELL CYCLE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CARDIOMYOPATHY; CELL CYCLE CHECKPOINT; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL DIVISION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; G2 PHASE CELL CYCLE CHECKPOINT; HEART FAILURE; HEART MUSCLE CELL; HEART SIZE; HEART VENTRICLE HYPERTROPHY; IMMUNOHISTOCHEMISTRY; MOUSE; NONHUMAN; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SURVIVAL; TRANSGENIC MOUSE; ANIMAL; CARDIOMEGALY; CELL CYCLE; ENZYMOLOGY; GENETICS; HEART MUSCLE; METABOLISM; MOUSE STRAIN; PATHOLOGY; SIGNAL TRANSDUCTION; TRANSGENE;

ANIMALS; ATRIAL NATRIURETIC FACTOR; CARDIOMEGALY; CELL CYCLE; CELL CYCLE PROTEINS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED STRAINS; MICE, TRANSGENIC; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIUM; RAS PROTEINS; TRANSGENES;

EID: 80052542319     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Ahujas P, Sdek P, MacLellan WR. 2007. Cardiac myocyte cell-cycle control in development, disease, and regeneration. Physiol Rev 87:521-544. (Pubitemid 47086282)
2. Bicknell KA, Brooks G. 2008. Reprogramming the cell-cycle machinery to treat cardiovascular disease. Curr Opin Pharmacol 8:193-201.
3. Bicknell KA, Surry EL, Brooks G. 2003. Targeting the cell-cycle machinery for the treatment of cardiovascular disease. J Pharm Pharmacol 55:571-591. (Pubitemid 36705569)
4. Brooks G, Poolman RA, Li JM. 1998. Arresting developments in the cardiac myocyte cell cycle: role of cyclin-dependent kinase inhibitors. Cardiovasc Res 39:301-311. (Pubitemid 28346526)
5. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouyssegur J. 1999. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth-factor-induced gene expression and cell-cycle entry. EMBO J 18:664-674. (Pubitemid 29057251)
6. Busk PK, Hinrichsen R, Bartkova J, Hansen AH, Christoffersen TE, Bartek J, Haunso S. 2005. Cyclin D2 induces proliferation of cardiac myocytes and represses hypertrophy. Exp Cell Res 304:149-161. (Pubitemid 40222084)
7. Chambard JC, Lefloch R, Pouyssegur J, Lenormand P. 2007. ERK implication in cell-cycle regulation. Biochim Biophys Acta 1773:1299-1310.
8. Clerk A, Cullingford TE, Fuller SJ, Giraldo A, Markou T, Pikkarainen S, Sugden PH. 2007. Signaling pathways mediating cardiac myocyte gene expression in physiological and stress responses. J Cell Physiol 212:311-322. (Pubitemid 47025620)
9. Errami M, Galindo CL, Tassa AT, Dimaio JM, Hill JA, Garner HR. 2008. Doxycycline attenuates isoproterenol- and transverse aortic banding-induced cardiac hypertrophy in mice. J Pharmacol Exp Ther 324:1196-1203. (Pubitemid 351397830)
10. Fung TK, Ma HT, Poon RY. 2007. Specialized roles of the 2 mitotic cyclins in somatic cells: cyclin A as an activator of M phase-promoting factor. Mol Biol Cell 18:1861-1873. (Pubitemid 46717566)
11. Hunter JJ, Tanaka N, Rockman HA, Ross J Jr, Chien KR. 1995. Ventricular expression of a MLC-2v-ras fusion gene induces cardiac hypertrophy and selective diastolic dysfunction in transgenic mice. J Biol Chem 270:23173-23178.
12. Institute for Laboratory Animal Research. 1996. Guide for the care and use of laboratory animals. Washington (DC): National Academies Press.
13. Kai H, Muraishi A, Sugiu Y, Nishi H, Seki Y, Kuwahara F, Kimura A, Kato H, Imaizumi T. 1998. Expression of protooncogenes and gene mutation of sarcomeric proteins in patients with hypertrophic cardiomyopathy. Circ Res 83:594-601. (Pubitemid 28427742)
14. Komuro I, Kurabayashi M, Takaku F, Yazaki Y. 1988. Expression of cellular oncogenes in the myocardium during the developmental stage and pressure-overloaded hypertrophy of the rat heart. Circ Res 62:1075-1079.
15. Lezoualc'h F, Metrich M, Hmitou I, Duquesnes N, Morel E. 2008. Small GTP-binding proteins and their regulators in cardiac hypertrophy. J Mol Cell Cardiol 44:623-632.
16. Li JM, Brooks G. 1997. Downregulation of cyclin-dependent kinase inhibitors p21 and p27 in pressure-overload hypertrophy. Am J Physiol 273:H1358-H1367.
17. Li JM, Brooks G. 1999. Cell-cycle regulatory molecules (cyclins, cyclin-dependent kinases, and cyclin-dependent kinase inhibitors) and the cardiovascular system: potential targets for therapy? Eur Heart J 20:406-420. (Pubitemid 29116537)
18. Li JM, Poolman RA, Brooks G. 1998. Role of G1 phase cyclins and cyclin-dependent kinases during cardiomyocyte hypertrophic growth in rats. Am J Physiol 275:H814-H822.
19. Mebratu Y, Tesfaigzi Y. 2009. How ERK1/2 activation controls cell proliferation and cell death: is subcellular localization the answer? Cell Cycle 8:1168-1175.
20. Mitchell S, Ota A, Foster W, Zhang B, Fang Z, Patel S, Nelson SF, Horvath S, Wang Y. 2006. Distinct gene expression profiles in adult mouse heart following targeted MAP kinase activation. Physiol Genomics 25:50-59.
21. Molina JR, Adjei AA. 2006. The Ras-Raf-MAPK pathway. J Thorac Oncol 1:7-9.
22. Nozato T, Ito H, Watanabe M, Ono Y, Adachi S, Tanaka H, Hiroe M, Sunamori M, Marum F. 2001. Overexpression of Cdk inhibitor p16INK4a by adenovirus vector inhibits cardiac hypertrophy in vitro and in vivo: a novel strategy for the gene therapy of cardiac hypertrophy. J Mol Cell Cardiol 33:1493-1504. (Pubitemid 32681667)
23. Oh WJ, Rishi V, Pelech S, Vinson C. 2007. Histological and proteomic analysis of reversible H-RasV12G expression in transgenic mouse skin. Carcinogenesis 28:2244-2252. (Pubitemid 47543387)
24. Poolman RA, Brooks G. 1998. Expressions and activities of cell-cycle regulatory molecules during the transition from myocyte hyperplasia to hypertrophy. J Mol Cell Cardiol 30:2121-2135. (Pubitemid 28495337)
25. Proud CG. 2004. Ras, PI3 kinase, and mTOR signaling in cardiac hypertrophy. Cardiovasc Res 63:403-413. (Pubitemid 38970184)
26. Regula KM, Rzeszutek MJ, Baetz D, Seneviratne C, Kirshenbaum LA. 2004. Therapeutic opportunities for cell cycle re-entry and cardiac regeneration. Cardiovasc Res 64:395-401. (Pubitemid 39505418)
27. Roberts PJ, Der CJ. 2007. Targeting the Raf-MEK-ERK mitogenactivated protein kinase cascade for the treatment of cancer. Oncogene 26:3291-3310. (Pubitemid 46763022)
28. Ruan H, Mitchell S, Vainoriene M, Lou Q, Xie LH, Ren S, Goldhaber JI, Wang Y. 2007. Gi α1-mediated cardiac electrophysiological remodeling and arrhythmia in hypertrophic cardiomyopathy. Circulation 116:596-605. (Pubitemid 47356345)
29. Stansfield WE, Rojas M, Corn D, Willis M, Patterson C, Smyth SS, Selzman CH. 2007. Characterization of a model to independently study regression of ventricular hypertrophy. J Surg Res 142:387-393. (Pubitemid 47418820)
30. Sugden PH. 2001. Signalling pathways in cardiac myocyte hypertrophy. Ann Med 33:611-622. (Pubitemid 34081499)
31. Sugden PH. 2003. Ras, Akt, and mechanotransduction in the cardiac myocyte. Circ Res 93:1179-1192. (Pubitemid 37543058)
32. Sugden PH, Clerk A. 1998. Cellular mechanisms of cardiac hypertrophy. J Mol Med 76:725-746. (Pubitemid 28475168)
33. Sugden PH, Clerk A. 2000. Activation of the small GTP-binding protein Ras in the heart by hypertrophic agonists. Trends Cardiovasc Med 10:1-8. (Pubitemid 32013923)
34. Tamamori M, Ito H, Hiroe M, Terada Y, Marumo F, Ikeda MA. 1998. Essential roles for G1 cyclin-dependent kinase activity in development of cardiomyocyte hypertrophy. Am J Physiol 275:H2036-H2040.
35. Thorburn A, Thorburn J, Chen SY, Powers S, Shubeita HE, Feramisco JR, Chien KR. 1993. hRas-dependent pathways can activate morphological and genetic markers of cardiac muscle cell hypertrophy. J Biol Chem 268:2244-2249. (Pubitemid 23033640)
36. van Amerongen MJ, Engel FB. 2008. Features of cardiomyocyte proliferation and its potential for cardiac regeneration. J Cell Mol Med 12:2233-2244.
37. Vinet L, Rouet-Benzineb P, Marniquet X, Pellegrin N, Mangin L, Louedec L, Samuel JL, Mercadier JJ. 2008. Chronic doxycycline exposure accelerates left ventricular hypertrophy and progression to heart failure in mice after thoracic aorta constriction. Am J Physiol Heart Circ Physiol 295:H352-H360.
38. Wei BR, Hoover SB, Ross MM, Zhou W, Meani F, Edwards JB, Spehalski EI, Risinger JI, Alvord WG, Quinones OA, Belluco C, Martella L, Campagnutta E, Ravaggi A, Dai RM, Goldsmith PK, Woolard KD, Pecorelli S, Liotta LA, Petricoin EF, Simpson RM. 2009. Serum S100A6 concentration predicts peritoneal tumor burden in mice with epithelial ovarian cancer and is associated with advanced stage in patients. PLoS ONE 4:e7670.
39. Woo YJ, Panlilio CM, Cheng RK, Liao GP, Atluri P, Hsu VM, Cohen JE, Chaudhry HW. 2006. Therapeutic delivery of cyclin A2 induces myocardial regeneration and enhances cardiac function in ischemic heart failure. Circulation 114:I206-I213. (Pubitemid 44297152)
40. Yu Z, Redfern CS, Fishman GI. 1996. Conditional transgene expression in the heart. Circ Res 79:691-697. (Pubitemid 26317816)
41. Zheng M, Dilly K, Dos Santos Cruz J, Li M, Gu Y, Ursitti JA, Chen J, Ross J Jr, Chien KR, Lederer JW, Wang Y. 2004. Sarcoplasmic reticulum calcium defect in Ras-induced hypertrophic cardiomyopathy heart. Am J Physiol Heart Circ Physiol 286:H424-H433. (Pubitemid 38049509)
42. Zhong W, Mao S, Tobis S, Angelis E, Jordan MC, Roos KP, Fishbein MC, de Alboran IM, MacLellan WR. 2006. Hypertrophic growth in cardiac myocytes is mediated by Myc through a cyclin D2-dependent pathway. EMBO J 25:3869-3879. (Pubitemid 44300272)